Last reviewed · How we verify
Placebo PF00299804
PF00299804 is a small-molecule tyrosine kinase inhibitor that targets EGFR and HER2 to block cancer cell growth signaling.
Dacomitinib (PF-00299804) is a second-generation, irreversible EGFR tyrosine kinase inhibitor developed by Pfizer. It has completed several clinical trials in advanced non-small cell lung cancer (NSCLC), showing promise in patients who have not responded to standard therapy. Despite no FDA approval, it has been evaluated for its efficacy and safety in multiple phases of clinical development.
At a glance
| Generic name | Placebo PF00299804 |
|---|---|
| Also known as | PF-00299804 |
| Sponsor | Pfizer |
| Drug class | EGFR/HER2 tyrosine kinase inhibitor |
| Target | EGFR, HER2 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
PF00299804 irreversibly inhibits epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) tyrosine kinases. By blocking these key growth signaling pathways, it prevents proliferation of cancer cells that depend on EGFR/HER2 activation. This dual targeting approach is designed to overcome resistance mechanisms seen with single-target EGFR inhibitors.
Approved indications
- Non-small cell lung cancer (NSCLC)
- HER2-positive breast cancer
Common side effects
- Diarrhea
- Rash
- Nausea
- Fatigue
- Vomiting